Results 31 to 40 of about 18,095,855 (237)

Solid-phase extraction of $^{225}$Ac using ion-imprinted resin and $^{243}$Am as a radioactive tracer for internal dosimetry and incorporation measurements

, 2022
Actinium-225 is a highly radiotoxic alpha-emitting radionuclide, which is currently in the spotlight owing to its promising radiotherapeutic applications in nuclear medicine. Personnel involved in the production and handling of actinium-225 is exposed to
Froidevaux, Pascal, Cusnir, Ruslan, Straub, Marietta, Carbonez, Pierre, Marietta Straub, Pierre Carbonez, Pascal Froidevaux, Ruslan Cusnir   +7 more
core   +1 more source

Supply and Clinical Application of Actinium-225 and Bismuth-213

Seminars in Nuclear Medicine, 2020
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia.
Morgenstern, Alfred, Apostolidis, Christos, Bruchertseifer, Frank   +2 more
openaire   +2 more sources

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

EJNMMI Radiopharmacy and Chemistry, 2023
Background The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist,
Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille   +9 more
doaj   +1 more source

Developing a Monte Carlo Simulation for Time- Series Analysis of Actinium-225 Decay [PDF]

, 2021
This report describes the development of a script programmed in the Python language designed to simulate radioactive decay using Monte Carlo methods. This is to conduct analysis on the equilibrium behavior of a specific radioactive decay chain, replacing
Wood, Victoria
core   +1 more source

Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free ²²⁵Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy

Pharmaceutics, 2021
Actinium-225 (225Ac) is a promising radionuclide used in targeted alpha therapy (TAT). Although 225Ac labeling of bifunctional chelating ligands is effective, previous in vivo studies reported that free 225Ac can be released from the drugs and that such ...
Mitsuyoshi Yoshimoto, Yukie Yoshii, Hiroki Matsumoto, Mitsuhiro Shinada, Masashi Takahashi, Chika Igarashi, Fukiko Hihara, Tomoko Tachibana, Ayano Doi, Tatsuya Higashi, Hirofumi Fujii, Kohshin Washiyama   +11 more
doaj   +1 more source

Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

EJNMMI Physics, 2021
Background Actinium-225 is an alpha-particle emitter under investigation for use in radiopharmaceutical therapy. To address limited supply, accelerator-produced 225Ac has been recently made available.
George Sgouros, Bin He, Nitya Ray, Dale L. Ludwig, Eric C. Frey   +4 more
doaj   +1 more source

Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?

Frontiers in Medicine, 2022
Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation are locally delivered to tumor cells, while the surrounding healthy tissue is minimally affected.
Roger M. Pallares, Rebecca J. Abergel, Rebecca J. Abergel   +2 more
doaj   +1 more source

Alpha Therapy Beyond TOC and TATE—Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3

Pharmaceuticals
Objectives: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) commonly relies on somatostatin receptor subtype 2 (SSTR2) agonists such as DOTA-TOC/TATE, which may show limited efficacy due to high hepatic uptake and therapy ...
Lukas Greifenstein, Marcel Martin, Sarah Stephan, Aleksandr Eismant, Carsten S. Kramer, Christian Landvogt, Corinna Mueller, Frank Rösch, Richard P. Baum   +8 more
doaj   +1 more source

Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers

Bioengineering & Translational Medicine, 2022
Partial and/or heterogeneous irradiation of established (i.e., large, vascularized) tumors by α‐particles that exhibit only a 4–5 cell‐diameter range in tissue, limits the therapeutic effect, since regions not being hit by the high energy α‐particles are
Dominick Salerno, Alaina Howe, Omkar Bhatavdekar, Anders Josefsson, Jesus Pacheco‐Torres, Zaver M. Bhujwalla, Kathleen L. Gabrielson, Stavroula Sofou   +7 more
doaj   +1 more source

Actinium-225 Production via Proton Irradiation of Thorium-232 [PDF]

, 2016
High energy proton spallation reactions on natural thorium metal targets have been utilized to produce multi mCi [milliCurie] quantities of Actinium-225.
Griswold, Justin Reed
core